Zakia Belaid-Sandal

THERANOVIR is a young innovative Health-Tech company of Research and Development of breakthrough therapies in 3 fields of closely related pathologies, Cancer, Obesity and associated metabolic diseases and Infectious Diseases by targeting a platform of signaling pathways regulated by the protein complex NRP-1/OBR, newly discovered by the CEO/CSO Dr. Zakia BELAID-SANDAL (PhD). THERANOVIR benefits from a global and exclusive license from INSERM transfert for the valuation of 2 families of granted patents in Europe, United States and Japan. THERANOVIR filed its own patent in January 2023. THERANOVIR is a winner of the Lab-SHAKER 2017 (Genopole), Onco-Entrepreneurs 2018 (Cancer Campus, Villejuif), HEC-Challenge+ 2019 (HEC Paris), Ilab2020 (Ministry of education and research), and Innov'up PIA 2021 (Ile-de-France region) competitions.